Target intelligence / Profile preview

Vipera ammodytes venom

Molecular classification
Enzyme, Toxin, Phospholipase A2, Snake venom metalloproteinase, Serine protease, L-amino acid oxidase, C-type lectin-like protein
01

Overview

Vipera ammodytes venom is the complex toxic secretion of the long-nosed viper, widely regarded as the most dangerous snake in Europe due to its potent venom and significant yield. The venom is a heterogeneous mixture of proteins and peptides, primarily dominated by secreted phospholipases A2 (sPLA2s), such as the presynaptically neurotoxic ammodytoxins, as well as snake venom metalloproteinases (SVMPs) and serine proteases (Toxins, 2011, 3(7), 718-738). These components act synergistically to induce a range of clinical manifestations, including severe local tissue damage, systemic hemorrhage, and life-threatening neurotoxicity by blocking neurotransmitter release at the neuromuscular junction (Journal of Proteomics, 2015, 126, 25-40). In clinical toxicology, the venom is the therapeutic target for antivenoms, which utilize purified antibodies to sequester and neutralize the circulating toxins. Emerging research also focuses on small-molecule inhibitors like varespladib (a PLA2 inhibitor) and metalloproteinase inhibitors to provide rapid, field-stable treatments that can mitigate the enzymatic destruction caused by the venom before hospital-based antivenom can be administered (Scientific Reports, 2020, 10, 11245).

Other names
Long-nosed viper venomHorned viper venomNose-horned viper venomSand viper venomVipera ammodytes ammodytes venom
02

Mechanism of action

Neutralization of toxic proteins by specific antibodies and competitive inhibition of enzymatic activity by small molecules.

03

Biological functions

ProteolysisCell deathNeurotransmission disruptionHemolysisPlatelet aggregation inhibition
04

Disease associations

Snakebite envenomationHemorrhageNeurotoxicityInflammationAcute kidney injury
05

Safety considerations

Anaphylaxis to antivenomSerum sicknessTissue necrosisSecondary infectionCompartment syndrome
06

Interacting drugs

Vipera ammodytes antivenom

4 more in the full profile.

07

Biomarkers

Prothrombin time (PT)Activated partial thromboplastin time (aPTT)Creatine kinase (CK)Fibrinogen levelPlatelet countLactate dehydrogenase (LDH)

Beyond the preview

Go deeper on Vipera ammodytes venom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vipera ammodytes venom.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call